Washington State has enacted legislation that would require drug manufacturers to report detailed 340B sales and discount data at the state level beginning April 1, 2027.
At the same time, manufacturers have legal challenges in place, and the law may ultimately be delayed, revised, or overturned.
But regardless of the outcome, the law reflects a broader reality that manufacturers cannot ignore: 340B program data is increasingly intersecting with state transparency and compliance expectations. That intersection, not the fate of a single statute, is what manufacturers must be prepared to manage.
The law: expanding state visibility into 340B activity
If implemented, Washington’s law would require manufacturers to annually report:
- 340B units distributed to covered entities and contract pharmacies within the state
- Aggregate 340B discounts by drug
- Average discounts for high‑volume 340B drugs
This represents a shift from traditional federal‑only oversight toward state‑level scrutiny tied directly to manufacturers’ operational data.
Even if this specific law is challenged successfully, it sets a precedent that other states may follow.
340B management and compliance: where complexity already exists
For manufacturers, 340B compliance is already heavily regulated and operationally complex. It requires:
- Accurate identification of 340B‑eligible transactions
- Proper chargeback processing
- Alignment with government pricing requirements
- Complete, auditable transaction‑level records
In most organizations, the data required to support this compliance originates during commercial chargeback processing, not in downstream reporting tools.
The challenge is not access to data, it’s control, consistency, and defensibility when that data is needed for new reporting purposes.
Where the law, 340B, and compliance intersect
Washington’s requirement sits squarely at the intersection of:
- Commercial operations (chargebacks and distribution data)
- Government pricing and 340B compliance
- State transparency reporting
Manufacturers managing these functions in siloed systems often face the same risk: they must reconstruct 340B data after the fact—under deadline pressure and regulatory scrutiny. That introduces unnecessary compliance and reporting risk.
How iContracts supports all three
The iContracts Revenue Management Suite by Medispend is designed to actively process and manage revenue transactions, not simply report on them after the fact.
Because 340B discounts are operationalized through commercial chargebacks, the data required for 340B compliance and reporting is created during payment processing.
iContracts enables manufacturers to:
- Capture 340B sales and discount data at the point of transaction
- Maintain transaction‑level visibility across covered entities and contract pharmacies
- Centralize chargeback, contract, and revenue data in a single system
- Preserve clean audit trails that support both compliance and reporting needs
Rather than piecing together information from multiple sources, manufacturers can rely on revenue‑grade data that is already structured, reconciled, and defensible.
Why preparation still matters
Even if Washington’s law is overturned, the direction of regulatory travel is clear. State‑level transparency efforts are increasingly drawing on data that originates in revenue management and 340B operations.
Manufacturers that prepare now, by centralizing and governing that data, will be better positioned to respond quickly and confidently to future requirements.
The takeaway
This law may change. The operational reality behind it will not. Manufacturers that manage 340B data, compliance, and reporting through connected revenue management infrastructure will be far better equipped to adapt, without reactive data reconstruction or increased risk
Ready to see the reimagined iContracts in action? Schedule a demo or email us at solutions@medispend.com.
Katherine Johnson
Director, Government Pricing
